Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 3/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6703453 | 1.00 | TACR1 (0.56) | TACR1CTRB1CTSLCTSBCTSS | |
| SCHEMBL6368183 | 0.88 | GAA (0.53) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL6368188 | 0.88 | GAA (0.53) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL29129580 | 0.86 | CTSK (0.53) | CTRB1CTSLCTSBCTSSCTSK | |
| SCHEMBL6216881 | 0.86 | CASP1 (0.55) | MMEECE1 | |
| SCHEMBL5030269 | 0.86 | TACR1 (0.53) | TACR1CTRB1CTSLCTSBCTSS | |
| SCHEMBL220648 | 0.86 | TACR1 (0.68) | TACR1CTRB1CTSLCTSBCTSS | |
| SCHEMBL7372270 | 0.86 | TACR1 (0.68) | TACR1CTRB1CTSLCTSBCTSS | |
| SCHEMBL479010 | 0.86 | TACR1 (0.68) | TACR1CTRB1CTSLCTSBCTSS | |
| SCHEMBL219151 | 0.86 | TACR1 (0.68) | TACR1CTRB1CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024000-A1 | Dihydropyrimidine derivatives as cysteine protease inhibitors | NAEJA PHARMACEUTICAL INC. (CA) | 2004-02-05 | — | — | US | disclosed |
| EP-1326848-A1 | DIHYDROPYRIMIDINE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | Naeja Pharmaceutical Inc. (CA) | 2003-07-16 | — | — | EP | disclosed |
| US-6569847-B1 | Inhibitors of cathepsins for treating muscular dystrophy, osteoporosis, rheumatoid arthritis, neuronal or cardiac ischaemia, allergy, or Chagas disease | NAEJA PHARMACEUTICALS INC. (CA) | 2003-05-27 | — | — | US | disclosed |
| WO-2002032879-A1 | DIHYDROPYRIMIDINE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2002-04-25 | — | — | WO | disclosed |
| EP-1165506-A1 | SUBSTITUTED AZETIDIN-2-ONES AS CYSTEINE PROTEASE INHIBITORS | Naeja Pharmaceutical Inc. (CA) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059881-A1 | SUBSTITUTED AZETIDIN-2-ONES AS CYSTEINE PROTEASE INHIBITORS | NAEJA PHARMACEUTICAL INC (CA) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024000-A1 | Dihydropyrimidine derivatives as cysteine protease inhibitors | DPEP1, DNPEP, PEPD | TACR1 1735/4885CTRB1 82/4885CTSL 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.